Login Register Cart 0
Review Article

Exploring the SARS-Cov-2 Main Protease (Mpro) and RdRp Targets by Updating Current Structure-based Drug Design Utilizing Co-crystals to Combat COVID-19

Author(s): H. Tarannum, K.M. Rashmi and S. Nandi*

Volume 23, Issue 8, 2022

Published on: 06 September, 2021

Page: [802 - 817] Pages: 16

DOI: 10.2174/1389450122666210906154849

Price: $65

Abstract

The unprecedented pandemic of COVID-19 caused by the novel strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) engulfs millions of death worldwide. It has directly hit the socio-economic status of the affected countries. There are more than 219 countries badly affected by the COVID-19. There are no particular small molecule inhibitors to combat the dreadful virus. Many antivirals, antimalarials, antiparasitic, antibacterials, immunosuppressive antiinflammatory, and immune stimulatory agents have been repurposed for the treatment of COVID-19. But the exact mechanism of action of these drugs towards COVID-19 targets has not been experimented with yet. Under the effect of chemotherapeutics, the virus may change its genetic material and produces various strains, which are the main reasons behind the dreadful attack of COVID-19. The nuclear genetic components are composed of main protease and RNA-dependent RNA polymerase (RdRp) which are responsible for producing nascent virion and viral replication in the host cells. To explore the biochemical mechanisms of various small molecule inhibitors, structure-based drug design can be attempted utilizing NMR crystallography. The process identifies and validates the target protein involved in the disease pathogenesis by the binding of a chemical ligand at a well-defined pocket on the protein surface. In this way, the mode of binding of the ligands inside the target cavity can be predicted for the design of potent SARS-CoV-2 inhibitors.

Keywords: COVID-19, SARS-CoV-2, Main protease, RNA dependent RNA polymerase (RdRp), co-crystallized ligand, mode of binding, structure-based crystallography.

« Previous Next »
Graphical Abstract

[1]
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798): 270-3.
[http://dx.doi.org/10.1038/s41586-020-2012-7] [PMID: 32015507]
[2]
Yang H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achilles’ heel of coronaviruses. Curr Pharm Des 2006; 12(35): 4573-90.
[http://dx.doi.org/10.2174/138161206779010369] [PMID: 17168763]
[3]
Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012; 4(6): 1011-33.
[http://dx.doi.org/10.3390/v4061011] [PMID: 22816037]
[4]
Hilgenfeld R. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J 2014; 281(18): 4085-96.
[http://dx.doi.org/10.1111/febs.12936] [PMID: 25039866]
[5]
Chang CK, Lo SC, Wang YS, Hou MH. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov Today 2016; 21(4): 562-72.
[http://dx.doi.org/10.1016/j.drudis.2015.11.015] [PMID: 26691874]
[6]
Paules CI, Marston HD, Fauci AS. Coronavirus infections-More than just the common cold. JAMA 2020; 323(8): 707-8.
[http://dx.doi.org/10.1001/jama.2020.0757] [PMID: 31971553]
[7]
Saif LJ. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? Rev Sci Tech 2004; 23(2): 643-60.
[http://dx.doi.org/10.20506/rst.23.2.1513] [PMID: 15702725]
[8]
Al-Osail AM, Al-Wazzah MJ. The history and epidemiology of Middle East respiratory syndrome corona virus. Multidiscip Respir Med 2017; 12(20): 20.
[http://dx.doi.org/10.1186/s40248-017-0101-8] [PMID: 28794876]
[9]
J Alsaadi EA. Jones IM. Membrane binding proteins of coronaviruses. Future Virol 2019; 14(4): 275-86.
[http://dx.doi.org/10.2217/fvl-2018-0144] [PMID: 32201500]
[10]
Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J 2019; 16(1): 69.
[http://dx.doi.org/10.1186/s12985-019-1182-0] [PMID: 31133031]
[11]
Verheije MH, Hagemeijer MC, Ulasli M, et al. The coronavirus nucleocapsid protein is dynamically associated with the replication-transcription complexes. J Virol 2010; 84(21): 11575-9.
[http://dx.doi.org/10.1128/JVI.00569-10] [PMID: 20739524]
[12]
McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses 2014; 6(8): 2991-3018.
[http://dx.doi.org/10.3390/v6082991] [PMID: 25105276]
[13]
Guo Y, Korteweg C, McNutt MA, Gu J. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res 2008; 133(1): 4-12.
[http://dx.doi.org/10.1016/j.virusres.2007.01.022] [PMID: 17825937]
[14]
Sutton G, Fry E, Carter L, et al. The nsp9 replicase protein of SARS-coronavirus, structure and functional insights. Structure 2004; 12(2): 341-53.
[http://dx.doi.org/10.1016/j.str.2004.01.016] [PMID: 14962394]
[15]
Jiang Y, Yin W, Xu HE. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19. Biochem Biophys Res Commun 2021; 538: 47-53.
[http://dx.doi.org/10.1016/j.bbrc.2020.08.116] [PMID: 32943188]
[16]
Risco C, Rodríguez JR, López-Iglesias C, Carrascosa JL, Esteban M, Rodríguez D. Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol 2002; 76(4): 1839-55.
[http://dx.doi.org/10.1128/JVI.76.4.1839-1855.2002] [PMID: 11799179]
[17]
Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020; 92(4): 418-23.
[http://dx.doi.org/10.1002/jmv.25681] [PMID: 31967327]
[18]
Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015; 1282: 1-23.
[http://dx.doi.org/10.1007/978-1-4939-2438-7_1] [PMID: 25720466]
[19]
V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 2021; 19(3): 155-70.
[http://dx.doi.org/10.1038/s41579-020-00468-6] [PMID: 33116300]
[20]
Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Ménard R. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 2005; 79(24): 15199-208.
[http://dx.doi.org/10.1128/JVI.79.24.15199-15208.2005] [PMID: 16306591]
[21]
Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2020; 35(1): 145-51.
[http://dx.doi.org/10.1080/14756366.2019.1690480] [PMID: 31724441]
[22]
Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay. J Virol 2020; 94(22): e01265-20.
[http://dx.doi.org/10.1128/JVI.01265-20] [PMID: 32843534]
[23]
Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors. Science 2020; 368(6489): 409-12.
[http://dx.doi.org/10.1126/science.abb3405] [PMID: 32198291]
[24]
Hu T, Zhang Y, Li L, et al. Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different con-formational changes in crystal structure. Virology 2009; 388(2): 324-34.
[http://dx.doi.org/10.1016/j.virol.2009.03.034] [PMID: 19409595]
[25]
Hsu MF, Kuo CJ, Chang KT, et al. Mechanism of the maturation process of SARS-CoV 3CL protease. J Biol Chem 2005; 280(35): 31257-66.
[http://dx.doi.org/10.1074/jbc.M502577200] [PMID: 15788388]
[26]
Barretto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 2005; 79(24): 15189-98.
[http://dx.doi.org/10.1128/JVI.79.24.15189-15198.2005] [PMID: 16306590]
[27]
Han YS, Chang GG, Juo CG, et al. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry 2005; 44(30): 10349-59.
[http://dx.doi.org/10.1021/bi0504761] [PMID: 16042412]
[28]
Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019; 10(1): 2342.
[http://dx.doi.org/10.1038/s41467-019-10280-3] [PMID: 31138817]
[29]
Ahn DG, Choi JK, Taylor DR, Oh JW. Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates. Arch Virol 2012; 157(11): 2095-104.
[http://dx.doi.org/10.1007/s00705-012-1404-x] [PMID: 22791111]
[30]
Subissi L, Posthuma CC, Collet A, et al. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci USA 2014; 111(37): E3900-9.
[http://dx.doi.org/10.1073/pnas.1323705111] [PMID: 25197083]
[31]
McDonald SM. RNA synthetic mechanisms employed by diverse families of RNA viruses. Wiley Interdiscip Rev RNA 2013; 4(4): 351-67.
[http://dx.doi.org/10.1002/wrna.1164] [PMID: 23606593]
[32]
Gao Y, Yan L, Huang Y, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 2020; 368(6492): 779-82.
[http://dx.doi.org/10.1126/science.abb7498] [PMID: 32277040]
[33]
Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science 2020; 368(6498): 1499-504.
[http://dx.doi.org/10.1126/science.abc1560] [PMID: 32358203]
[34]
Wang Q, Wu J, Wang H, et al. Structural basis for RNA replication by the SARS-CoV-2 polymerase. Cell 2020; 182(2): 417-428.e13.
[http://dx.doi.org/10.1016/j.cell.2020.05.034] [PMID: 32526208]
[35]
Kendrew JC, Bodo G, Dintzis HM, Parrish RG, Wyckoff H, Phillips DC. A three-dimensional model of the myoglobin molecule obtained by x-ray analysis. Nature 1958; 181(4610): 662-6.
[http://dx.doi.org/10.1038/181662a0] [PMID: 13517261]
[36]
Congreve M, Murray CW, Blundell TL. Structural biology and drug discovery. Drug Discov Today 2005; 10(13): 895-907.
[http://dx.doi.org/10.1016/S1359-6446(05)03484-7] [PMID: 15993809]
[37]
Nandi S, Kumar M, Saxena M, Saxena AK. The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat covid-19 utilizing structure-based molecular docking. Comb Chem High Throughput Screen 2020.
[http://dx.doi.org/10.2174/1386207323999200824115536] [PMID: 32838713]
[38]
Meyer EF. The first years of the Protein Data Bank. Protein Sci 1997; 6(7): 1591-7.
[http://dx.doi.org/10.1002/pro.5560060724] [PMID: 9232661]
[39]
St John SE, Tomar S, Stauffer SR, Mesecar AD. Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4-The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). Bioorg Med Chem 2015; 23(17): 6036-48.
[http://dx.doi.org/10.1016/j.bmc.2015.06.039] [PMID: 26190463]
[40]
Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun 2020; 11(1): 5047-7.
[http://dx.doi.org/10.1038/s41467-020-18709-w] [PMID: 33028810]
[41]
Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020; 582(7811): 289-93.
[http://dx.doi.org/10.1038/s41586-020-2223-y] [PMID: 32272481]
[42]
Su HX, Yao S, Zhao WF, et al. Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacol Sin 2020; 41(9): 1167-77.
[http://dx.doi.org/10.1038/s41401-020-0483-6] [PMID: 32737471]
[43]
Availalble from: https://www.rcsb.org/structure/6W63
[44]
Ma C, Sacco MD, Hurst B, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. bioRxiv 2020.2020.04.20.051581.
[http://dx.doi.org/10.1038/s41422-020-0356-z] [PMID: 32511378]
[45]
Goyal B, Goyal D. Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy. ACS Comb Sci 2020; 22(6): 297-305.
[http://dx.doi.org/10.1021/acscombsci.0c00058] [PMID: 32402186]
[46]
Jin Z, Zhao Y, Sun Y, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 2020; 27(6): 529-32.
[http://dx.doi.org/10.1038/s41594-020-0440-6] [PMID: 32382072]
[47]
Availalble from: https://www.rcsb.org/structure/7JYC
[48]
Dai W, Zhang B, Jiang XM, et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science 2020; 368(6497): 1331-5.
[http://dx.doi.org/10.1126/science.abb4489] [PMID: 32321856]
[49]
Prongay AJ, Guo Z, Yao N, et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based op-timization. J Med Chem 2007; 50(10): 2310-8.
[http://dx.doi.org/10.1021/jm060173k] [PMID: 17444623]
[50]
Kim Y, Lovell S, Tiew KC, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and corona-viruses. J Virol 2012; 86(21): 11754-62.
[http://dx.doi.org/10.1128/JVI.01348-12] [PMID: 22915796]
[51]
Yang H, Xie W, Xue X, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol 2005; 3(10): e324.
[http://dx.doi.org/10.1371/journal.pbio.0030324] [PMID: 16128623]
[52]
Zhang L, Zhou R. Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase. J Phys Chem B 2020; 124(32): 6955-62.
[http://dx.doi.org/10.1021/acs.jpcb.0c04198] [PMID: 32521159]
[53]
Nandi S, Roy H, Gummadi A, Saxena A. Exploring spike protein as potential target of novel coronavirus and to inhibit the viability uti-lizing natural agents. Curr Drug Targets 2021; 22: 1-15.
[http://dx.doi.org/10.2174/1389450122666210309105820] [PMID: 33687893]
[54]
Badshah SL, Riaz A, Muhammad A, et al. Isolation, characterization, and medicinal potential of polysaccharides of Morchella esculenta. Molecules 2021; 26(5): 1-12.
[http://dx.doi.org/10.3390/molecules26051459] [PMID: 33800212]
[55]
Ullah A, Munir S, Badshah SL, et al. Important flavonoids and their role as a therapeutic agent. Molecules 2020; 25(22): 5243.
[http://dx.doi.org/10.3390/molecules25225243] [PMID: 33187049]
[56]
Emwas AH, Szczepski K, Poulson BG, et al. NMR as a “gold standard” method in drug design and discovery. Molecules 2020; 25(20): 4597.
[http://dx.doi.org/10.3390/molecules25204597] [PMID: 33050240]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy